XXXX : long-term follow-up and patterns of failure.

@entity1 @entity632 @entity5 @entity1161 @entity2262 @entity880 @entity1349 @entity4740
PURPOSE: To analyze the long-term outcomes and pattern of failures for @entity5 . METHODS AND MATERIALS: A retrospective review of all @entity1 with @entity5 presented to our institution between 1978 and 1993 was performed. One hundred ten @entity1 were eligible and form the basis of this analysis. Fifty-seven @entity1 were male. The median age was 57 years (range: 21-82 years). The treatments were as follows: chemotherapy alone ( @entity4740 ), 39 @entity1 ; combined modality with @entity1161 ( @entity1161 ), 69; radiation therapy alone, 2. Radiation therapy fields were as follows: regional, 13 @entity1 ; extended, 6; subtotal, 44; and central lymphatic, 8. The median number of chemotherapy cycles was 8, and 98 @entity1 received @entity632 -containing regimens. Enough information was available to calculate the International Prognostic Index for 107 @entity1 . The following prognostic factors were examined for predictive value in @entity1349 ( @entity1349 ) and freedom from progression (FFP) by univariate and multivariate analyses: International Prognostic Index, gender, @entity880 dehydrogenase (LDH) (normal vs. elevated), B symptoms, performance status, @entity2262 , presence or absence of a bulky disease, age (</= vs. >60 years), number of sites of involvement, treatment ( @entity4740 vs. @entity1161 ), and pathology. To minimize @entity1 selection biases given the nature of the retrospective analysis, the patterns of relapse were analyzed only for the @entity1 who achieved a complete response. RESULTS: The median follow-up for the alive @entity1 was 9.5 years (range: 1.1-19.5 years). Complete response was achieved in 80 @entity1 : 24 of 39 @entity1 in the @entity4740 group (62%), 54 of 69 @entity1 in the @entity1161 group (78%), and 2 of 2 @entity1 in the radiation therapy alone group. The actuarial 5- and 10-year @entity1349 rates were 65% and 42%, respectively. The 5- and 10-year FFP was 42% and 26%, respectively. Significant prognostic factors by multivariate analyses were age and LDH for @entity1349 and LDH for FFP. For complete responders, 5-year freedom from recurrence in the original sites of involvement (with or without recurrence in the new sites) was 43% for @entity4740 and 60% for @entity1161 @entity1 (p = 0.03, Wilcoxon). Five-year freedom from isolated recurrence in the original sites of involvement was 60% for @entity4740 and 69% for @entity1161 @entity1 (p = 0.17). The 5-year overall FFP was 43% for @entity4740 @entity1 and 56% for @entity1161 @entity1 (p = 0.06). CONCLUSION: Combined modality treatment seems to give an advantage in terms of disease control in the primary sites compared to chemotherapy alone, though the advantages in @entity1349 and FFP were not statistically significant in our @entity1 population. By multivariate analyses, LDH was a significant prognostic indicator for @entity1349 and FFP, whereas age was for @entity1349 .
